Filing Details

Accession Number:
0001209191-23-038343
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-20 16:07:09
Reporting Period:
2023-06-15
Accepted Time:
2023-06-20 16:07:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557290 A Stuart Arbuckle C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-15 8,603 $187.53 65,159 No 4 M Direct
Common Stock Disposition 2023-06-15 8,603 $349.00 56,556 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-06-15 8,603 $0.00 8,603 $187.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,603 2029-02-05 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 140 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
  2. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  3. Open market sales reported on this line occurred at a weighted average price of $349.00 (range $349.00 to $349.02).
  4. Fully vested.